In order to be eligible to file a claim form and receive a cash distribution from the proposed Settlement, you must be a person or entity in the
United States who paid or provided reimbursement for some or all of the purchase price of branded EpiPen® or EpiPen Jr® (collectively, “EpiPen”)
devices or authorized generic versions of EpiPen devices for the purpose of consumption, and not resale, by yourself or your family member(s) at
any time between August 24, 2011, and November 1, 2020.
Several groups are excluded from the Class and are not eligible to file a claim form and receive a cash distribution from the proposed Settlement,
even if they otherwise meet the definition above. The following groups are excluded from Class:
a. Any person or entity who is an officer, director, manager, employee, subsidiary, or affiliate of Pfizer, Inc., Meridian Medical Technologies, Inc.,
King Pharmaceuticals, Inc. (n/k/a King Pharmaceuticals LLC), Mylan N.V., Mylan Specialty L.P., or Mylan Pharmaceuticals Inc.
(together, the “Defendants”);
b. Insured consumers who purchased branded or authorized generic EpiPen devices only via a fixed dollar co-payment that is the same for all
covered devices, whether branded or generic, regardless of the price of the device (e.g., $20 for all branded and generic devices);
c. Consumers who purchased or received branded or authorized generic EpiPen devices only through a Medicaid program;
d. Consumers who only purchased branded or authorized generic EpiPen devices directly from one or more of the Defendants;
e. Any of the judges in this case and members of their immediate families;
f. Consumers whose only purchases of an EpiPen occurred before March 13, 2014, and;
g. Any person who has previously opted out of the Class in this case.